213 related articles for article (PubMed ID: 35008062)
1. Active Pharmacovigilance for Primaquine Radical Cure of Plasmodium vivax Malaria in Odisha, India.
Anvikar AR; Sahu P; Pradhan MM; Sharma S; Ahmed N; Yadav CP; Pradhan S; Duparc S; Grewal Daumerie P; Valecha N
Am J Trop Med Hyg; 2022 Jan; 106(3):831-840. PubMed ID: 35008062
[TBL] [Abstract][Full Text] [Related]
2. Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency.
Liu H; Zeng W; Malla P; Wang C; Lakshmi S; Kim K; Menezes L; Yang Z; Cui L
Infection; 2023 Feb; 51(1):213-222. PubMed ID: 35976559
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency.
Kheng S; Muth S; Taylor WR; Tops N; Kosal K; Sothea K; Souy P; Kim S; Char CM; Vanna C; Ly P; Ringwald P; Khieu V; Kerleguer A; Tor P; Baird JK; Bjorge S; Menard D; Christophel E
BMC Med; 2015 Aug; 13():203. PubMed ID: 26303162
[TBL] [Abstract][Full Text] [Related]
4. G6PD deficiency alleles in a malaria-endemic region in the Western Brazilian Amazon.
Dombrowski JG; Souza RM; Curry J; Hinton L; Silva NRM; Grignard L; Gonçalves LA; Gomes AR; Epiphanio S; Drakeley C; Huggett J; Clark TG; Campino S; Marinho CRF
Malar J; 2017 Jun; 16(1):253. PubMed ID: 28619120
[TBL] [Abstract][Full Text] [Related]
5. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Commons RJ; Simpson JA; Thriemer K; Chu CS; Douglas NM; Abreha T; Alemu SG; Añez A; Anstey NM; Aseffa A; Assefa A; Awab GR; Baird JK; Barber BE; Borghini-Fuhrer I; D'Alessandro U; Dahal P; Daher A; de Vries PJ; Erhart A; Gomes MSM; Grigg MJ; Hwang J; Kager PA; Ketema T; Khan WA; Lacerda MVG; Leslie T; Ley B; Lidia K; Monteiro WM; Pereira DB; Phan GT; Phyo AP; Rowland M; Saravu K; Sibley CH; Siqueira AM; Stepniewska K; Taylor WRJ; Thwaites G; Tran BQ; Hien TT; Vieira JLF; Wangchuk S; Watson J; William T; Woodrow CJ; Nosten F; Guerin PJ; White NJ; Price RN
BMC Med; 2019 Aug; 17(1):151. PubMed ID: 31366382
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria.
Taylor WRJ; Kim S; Kheng S; Muth S; Tor P; Christophel E; Mukaka M; Kerleguer A; Luzzatto L; Baird JK; Menard D
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009690. PubMed ID: 34495956
[TBL] [Abstract][Full Text] [Related]
7. Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.
Taylor WRJ; Kheng S; Muth S; Tor P; Kim S; Bjorge S; Topps N; Kosal K; Sothea K; Souy P; Char CM; Vanna C; Ly P; Khieu V; Christophel E; Kerleguer A; Pantaleo A; Mukaka M; Menard D; Baird JK
J Infect Dis; 2019 Oct; 220(11):1750-1760. PubMed ID: 31549159
[TBL] [Abstract][Full Text] [Related]
8. Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.
Awab GR; Imwong M; Bancone G; Jeeyapant A; Day NPJ; White NJ; Woodrow CJ
Am J Trop Med Hyg; 2017 Dec; 97(6):1782-1787. PubMed ID: 29141719
[TBL] [Abstract][Full Text] [Related]
9. Glucose-6-phosphate dehydrogenase deficiency prevalence and genetic variants in malaria endemic areas of Colombia.
Valencia SH; Ocampo ID; Arce-Plata MI; Recht J; Arévalo-Herrera M
Malar J; 2016 May; 15(1):291. PubMed ID: 27225440
[TBL] [Abstract][Full Text] [Related]
10. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
Rajasekhar M; Simpson JA; Ley B; Edler P; Chu CS; Abreha T; Awab GR; Baird JK; Bancone G; Barber BE; Grigg MJ; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Llanos-Cuentas A; Pukrittayakamee S; Rijal KR; Saravu K; Sutanto I; Taylor WRJ; Thriemer K; Watson JA; Guerin PJ; White NJ; Price RN; Commons RJ;
Lancet Infect Dis; 2024 Feb; 24(2):184-195. PubMed ID: 37748497
[TBL] [Abstract][Full Text] [Related]
11. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
[TBL] [Abstract][Full Text] [Related]
12. G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.
Avalos S; Mejia RE; Banegas E; Salinas C; Gutierrez L; Fajardo M; Galo S; Pinto A; Mejia A; Fontecha G
Malar J; 2018 Nov; 17(1):415. PubMed ID: 30409136
[TBL] [Abstract][Full Text] [Related]
13. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
[TBL] [Abstract][Full Text] [Related]
14. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.
Chu CS; Bancone G; Moore KA; Win HH; Thitipanawan N; Po C; Chowwiwat N; Raksapraidee R; Wilairisak P; Phyo AP; Keereecharoen L; Proux S; Charunwatthana P; Nosten F; White NJ
PLoS Med; 2017 Feb; 14(2):e1002224. PubMed ID: 28170391
[TBL] [Abstract][Full Text] [Related]
15. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries.
Recht J; Ashley EA; White NJ
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006230. PubMed ID: 29672516
[TBL] [Abstract][Full Text] [Related]
16. Modelling primaquine-induced haemolysis in G6PD deficiency.
Watson J; Taylor WR; Menard D; Kheng S; White NJ
Elife; 2017 Feb; 6():. PubMed ID: 28155819
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and molecular characterization of G6PD deficiency in two Plasmodium vivax endemic areas in Venezuela: predominance of the African A-(202A/376G) variant.
Vizzi E; Bastidas G; Hidalgo M; Colman L; Pérez HA
Malar J; 2016 Jan; 15():19. PubMed ID: 26753754
[TBL] [Abstract][Full Text] [Related]
18. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
[TBL] [Abstract][Full Text] [Related]
19. Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers.
Pukrittayakamee S; Jittamala P; Watson JA; Hanboonkunupakarn B; Leungsinsiri P; Poovorawan K; Chotivanich K; Bancone G; Chu CS; Imwong M; Day NPJ; Taylor WRJ; White NJ
Elife; 2024 Feb; 12():. PubMed ID: 38319064
[TBL] [Abstract][Full Text] [Related]
20. Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.
Taylor WRJ; Meagher N; Ley B; Thriemer K; Bancone G; Satyagraha A; Assefa A; Chand K; Chau NH; Dhorda M; Degaga TS; Ekawati LL; Hailu A; Hasanzai MA; Naddim MN; Pasaribu AP; Rahim AG; Sutanto I; Thanh NV; Tuyet-Trinh NT; Waithira N; Woyessa A; Dondorp A; von Seidlein L; Simpson JA; White NJ; Baird JK; Day NP; Price RN
PLoS Negl Trop Dis; 2023 Sep; 17(9):e0011522. PubMed ID: 37672548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
